Somatostatin Analogues for Neuroendocrine Tumors
(REMAIN Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a multicenter, randomized, open-label, phase III study comparing standard of care use of somatostatin analogues (SSAs) to standard of care observation in patients with neuroendocrine neoplasms following treatment with Peptide Receptor Radionuclide Therapy (PRRT) (ethanol-stabilized Lu-177 dotatate).
Who Is on the Research Team?
Nikolaos Trikalinos, MD, MS
Principal Investigator
Washington University School of Medicine
Are You a Good Fit for This Trial?
This trial is for adults with nonfunctional neuroendocrine tumors (carcinoid tumors) who have already received PRRT treatment. Participants should be in stable condition after PRRT and able to attend regular follow-ups.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Somatostatin Analogues
Trial Overview
The study compares two approaches after PRRT: continuing treatment with somatostatin analogues (SSAs) versus simply observing patients without further immediate medication. Patients are randomly assigned to one of these groups.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
Patients will receive SSA as per standard of care, starting within 3 months after PRRT. SSA administration (route of administration, dosing, and adjustments) is not dictated by this protocol, and SSAs may be given indefinitely.
Patients will be treated according to current standard of care guidelines.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Washington University School of Medicine
Lead Sponsor
Curium US LLC
Industry Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.